Table 2.
Overall survival rate of breast cancer patients who developed a second primary malignancy with different characteristics, n (%)
| Variables | 1-year | 3-years | 5-years | 10-years | 15-years | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Survival | Death | p | Survival | Death | p | Survival | Death | p | Survival | Death | p | Survival | Death | p | |
| Number | 163 (100.00) | 0 | 153 (89.57) | 10 (6.13) | 144 (88.34) | 19 (11.66) | 105 (64.42) | 58 (35.58) | 92 (56.44) | 71 (43.56) | |||||
| Age at BC diagnosis (years) | – | 1.000 | 0.145 | 0.147 | 0.015 | ||||||||||
| < 56 | 102 (100.00) | 0 | 96 (94.12) | 6 (5.88) | 93 (91.18) | 9 (8.82) | 70 (68.63) | 32 (31.37) | 65 (63.73) | 37 (36.28) | |||||
| ≥ 56 | 61 (100.00) | 0 | 57 (93.44) | 4 (6.56) | 51 (83.61) | 10 (16.39) | 35 (57.38) | 26 (42.62) | 27 (44.26) | 34 (55.74) | |||||
| Age at SPM diagnosis (years) | – | 1.000 | 0.983 | 0.418 | 0.011 | ||||||||||
| < 62 | 94 (100.00) | 0 | 88 (93.62) | 6 (6.38) | 83 (88.30) | 11 (11.70) | 63 (67.02) | 31 (32.98) | 61 (64.89) | 33 (35.11) | |||||
| ≥ 62 | 69 (100.00) | 0 | 65 (94.20) | 4 (5.80) | 61 (88.41) | 8 (11.59) | 42 (60.87) | 27 (39.13) | 31 (44.93) | 38 (55.07) | |||||
| TNM stage of BCa | – | 0.229 | 0.975 | 0.810 | 0.252 | ||||||||||
| I + II | 119 (100.00) | 0 | 111 (93.28) | 8 (6.72) | 105 (88.24) | 14 (11.76) | 79 (66.39) | 40 (33.61) | 70 (58.82) | 49 (41.18) | |||||
| III + IV | 12 (100.00) | 0 | 10 (83.33) | 2 (16.67) | 10 (83.33) | 2 (16.67) | 7 (58.33) | 5 (41.67) | 5 (41.67) | 7 (58.33) | |||||
| TNM stage of SPMa | – | 1.000 | 0.135 | < 0.001 | < 0.001 | ||||||||||
| I + II | 59 (100.00) | 0 | 57 (96.61) | 2 (3.39) | 57 (96.61) | 2 (3.39) | 52 (88.14) | 7 (11.86) | 50 (84.74) | 9 (15.25) | |||||
| III + IV | 36 (100.00) | 0 | 35 (97.22) | 1 (2.78) | 31 (86.11) | 5 (13.89) | 16 (44.44) | 20 (55.56) | 13 (36.11) | 23 (63.89) | |||||
| BC therapeutic hospital grade | – | 0.838 | 0.537 | 0.302 | 0.103 | ||||||||||
| Tertiary | 101 (100.00) | 0 | 94 (93.07) | 7 (6.93) | 88 (87.13) | 13 (12.87) | 62 (61.39) | 39 (38.61) | 52 (51.49) | 49 (48.51) | |||||
| Secondary | 62 (100.00) | 0 | 59 (95.16) | 3 (4.84) | 56 (90.32) | 6 (9.68) | 43 (69.35) | 19 (30.65) | 40 (64.52) | 22 (35.48) | |||||
| SPM therapeutic hospital grade | – | 0.896 | 0.537 | 0.338 | 0.042 | ||||||||||
| Tertiary | 125 (100.00) | 0 | 118 (94.40) | 7 (5.60) | 112 (89.60) | 13 (10.40) | 83 (66.40) | 42 (33.60) | 76 (60.80) | 49 (39.20) | |||||
| Secondary | 38 (100.00) | 0 | 35 (92.11) | 3 (7.89) | 32 (84.21) | 6 (15.79) | 22 (57.89) | 16 (42.11) | 16 (42.11) | 22 (57.89) | |||||
| Surgery for BCb | – | 1.000 | 0.269 | 0.761 | 0.859 | ||||||||||
| Yes | 80 (100.00) | 0 | 83 (94.32) | 5 (5.68) | 80 (90.91) | 8 (9.09) | 49 (61.25) | 31 (38.75) | 46 (57.50) | 34 (42.50) | |||||
| No | 58 (100.00) | 0 | 70 (93.33) | 5 (6.67) | 64 (85.33) | 11 (14.67) | 37 (63.79) | 21 (36.21) | 34 (58.62) | 24 (41.38) | |||||
| Surgery for SPM | – | 0.102 | 0.192 | < 0.001 | < 0.001 | ||||||||||
| Yes | 88 (100.00) | 0 | 82 (93.18) | 6 (6.82) | 77 (87.50) | 11 (12.50) | 68 (77.27) | 20 (22.73) | 62 (70.45) | 26 (29.55) | |||||
| No | 75 (100.00) | 0 | 64 (85.33) | 11 (14.67) | 60 (80.00) | 15 (20.00) | 37 (49.33) | 38 (50.67) | 30 (40.00) | 45 (60.00) | |||||
| SPM sitesc | |||||||||||||||
| Colon and rectum | – | 0.259 | 0.530 | 0.259 | 0.211 | ||||||||||
| Yes | 30 (100.00) | 0 | 30 (100.00) | 0 (0) | 28 (93.33) | 2 (6.67) | 22 (73.33) | 8 (26.67) | 20 (66.67) | 10 (33.33) | |||||
| No | 133 (100.00) | 0 | 123 (92.48) | 10 (7.52) | 116 (87.22) | 17 (12.78) | 83 (62.41) | 50 (37.59) | 72 (54.14) | 61 (45.86) | |||||
| Thyroid | – | 0.292 | 0.254 | < 0.001 | < 0.001 | ||||||||||
| Yes | 28 (100.00) | 0 | 28 (100.00) | 0 | 27 (96.43) | 1 (3.57) | 27 (96.43) | 1 (3.57) | 27 (96.43) | 1 (3.57) | |||||
| No | 135 (100.00) | 0 | 125 (92.59) | 10 (7.41) | 117 (86.67) | 18 (13.33) | 78 (57.78) | 57 (42.22) | 65 (48.15) | 70 (51.85) | |||||
| Lung and bronchus | – | 0.344 | 0.628 | 0.832 | 0.491 | ||||||||||
| Yes | 24 (100.00) | 0 | 21 (87.50) | 3 (12.50) | 20 (83.33) | 4 (16.67) | 15 (62.50) | 9 (37.50) | 12 (50.00) | 12 (50.00) | |||||
| No | 139 (100.00) | 0 | 132 (94.96) | 7 (5.04) | 124 (89.21) | 15 (10.79) | 90 (64.75) | 49 (35.25) | 80 (57.55) | 59 (42.45) | |||||
| Latency (years) | – | 0.002 | < 0.001 | 0.647 | 0.017 | ||||||||||
| ≤ 5 | 77 (94.81) | 0 | 67 (87.01) | 10 (12.99) | 58 (75.32) | 19 (24.68) | 51 (66.23) | 26 (33.77) | 51 (66.23) | 26 (33.77) | |||||
| > 5 | 86 (100.00) | 0 | 86 (100.00) | 0 (0) | 86 (100.00) | 0 (0) | 54 (62.79) | 32 (37.21) | 41 (47.67) | 45 (52.33) | |||||
Bold means statistic significance
BC breast cancer, TNM tumour node metastasis, SPM second primary malignancy
aPatients with an unclassified TNM stage were not included
bPatients with an unknown status of surgery were not included
cThe number of SPM sites in colon and rectum, thyroid and lung and bronchus ranked as the top three, were included